Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients

Journal of Clinical Pharmacology

Volumn 45, Issue 9, 2005, Pages 1048-1054

  Kemény, Vendel ^a   Molnár, Sándor ^b   Andrejkovics, Mónika ^b   Makai, Attila ^c   Csiba, László ^b  

^a Pest Megyei Flor Ferenc Korhaz   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Cerebral infarctions; Cognitive impairment; Functional TCD; Neuropsychology; Vinpocetine

Indexed keywords

PLACEBO; VASOACTIVE AGENT; VINPOCETINE;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BRAIN BLOOD FLOW; BRAIN CIRCULATION; BRAIN INFARCTION; BREATH HOLDING; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; FINGER; FOLLOW UP; HEMODYNAMICS; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; BRAIN; CEREBRAL INFARCTION; CEREBROVASCULAR CIRCULATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; TIME FACTORS; VINCA ALKALOIDS;

EID: 23944516257     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005279363     Document Type: Article

References (37)

1. Kalaria RN, Ballard C. Stroke and cognition. Curr Atheroscler Rep. 2001;3:334-339.
2. De Deyn PP, Goeman J, Engelborghs S, et al. From neuronal and vascular impairment to dementia. Pharmacopsychiatry. 1999; 32(suppl 1):17-24.
3. Pohjasvaara T, Mantyla R, Salonen O, et al. How complex interactions of ischemic brain infarcts, white matter lesions, and atrophy relate to poststroke dementia. Arch Neurol. 2000;57:1295-1300.
4. Amar K, Wilcock G. Vascular dementia. BMJ. 1996;312:227-231.
5. Brust JCM. Vascular dementia reconsidered: part II. Cerebrovasc Dis. 1993;18:2-12.
6. Wentzel C, Rockwood K, MacKnight C, et al. Progression of impairment in patients with vascular cognitive impairment without dementia. Neurology. 2001;57:714-719.
7. Bíró K, Kárpáti E, Szporny L. Protective activity of ethyl apovincaminate on ischaemic anoxia of the brain. Arzneimittelforschung. 1976;26:1918-1920.
8. Csiba L, Kerényi L, Tron L, et al. Effect of vinpocetine on hemodynamics and glucose metabolism of chronic stroke patients. J Neurol Sci. 1997;150:79-79.
9. Fényes S, Földes J. Radiocirculographic study of the effect of ethyl apovincaminate on the cerebral circulation. Arzneimittelforschung. 1976;26:1963-1964.
10. Hadjiev D, Yancheva S. Rheoencephalographic and psychological studies with ethyl apovincaminate incerebral vascular insufficiency. Arzneimittelforschung. 1976;26:1947-1950.
11. Hayakawa M. Effect of vinpocetine on red blood cell deformability in stroke patients. Arzneimittelforschung. 1992;42:425-427.
12. Kárpáti E, Szporny L. General and cerebral haemodynamic activity of ethyl apovincaminate. Arzneimittelforschung. 1976;26:1908-1912.
13. Kiss E. Adjuvant effect of Cavinton in the treatment of climacteric symptoms. Ther Hung. 1990;38:170-173.
14. Kiss B, Karpati E. Mechanism of action of vinpocetine [in Hungarian]. Acta Pharm Hung. 1996;66:213-224.
15. Orosz É, Deák Gy, Benoist Gy. Effect of ethyl apovincaminate on the cerebral circulation: serial angiography and regional cerebral circulation studies in neurosurgical patients. Arzneimittelforschung. 1976;26:1951-1956.
16. Tohgi H, Sasaki K, Chiba K, et al. Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneim Forsch Drug Res. 1990;40:640-643.
17. Vámosi B, Molnár L, Demeter J, et al. Comparative study of the effect of ethyl apovincaminate and xantinol nicotinate in cerebrovascular diseases. Arzneimittelforschung. 1976;26:1980-1984.
18. Szakáll S, Boros I, Balkay L, et al. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J Neuroimaging. 1998;8:197-204.
19. Klingelhöfer J, Matzander G, Sander D, et al. Assessment of functional hemispheric asymmetry by bilateral simultaneous cerebral blood flow velocity monitoring. J Cereb Blood Flow Metab. 1997; 17:577-585.
20. Marcos A, Egido JA, Barquero M, et al. Full range of vasodilation tested by transcranial Doppler in the differential diagnosis of vascular and Alzheimer types of dementia. Cerebrovasc Dis. 1997;7:14-18.
21. Matteis M, Silvestrini M, Troisi E, et al. Cerebral hemodynamic patterns during stimuli in multi-infarct and Alzheimer types of dementia. Acta Neurol Scand. 1998;97:374-380.
22. Silvestrini M, Cupini LM, Matteis M, et al. Bilateral simultaneous assessment of cerebral flow velocity during mental activity. J Cereb Blood Flow Metab. 1994;14:643-648.
23. Tiecks FP, Haberl RL, Newel DW. Temporal patterns of evoked cerebral blood flow during reading. J Cereb Blood Flow Metab. 1998; 18:735-741.
24. Knecht S, Deppe M, Ebner A, et al. Noninvasive determination of language lateralization by functional transcranial Doppler sonography. Stroke. 1998;29:82-86.
25. Annett M. Hand preference and the laterality of cerebral speech. Cortex. 1975;11:305-328.
26. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical guide for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189-198.
27. Shulman KI, Shedletzky R, Silver IL. The challenge of time: clock drawing and cognitive function in the elderly. Int J Geriatr Psychiatry. 1986;1:135-140.
28. Manos PJ, Wu R. The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. Int J Psych Med. 1994;24:229-244.
29. Kálmán J, Maglóczky E, Janka Z. Clock drawing test: a simple and rapid test for dementia screening [in Hungarian]. Psychiatria Hungarica. 1995;10:11-18.
30. Benton AL. The Revised Visual Retention Test. 4th ed. New York, NY: Psychological Corporation; 1974.
31. Oswald WD, Fleischmann UM. NAI (Nürnberger Alters Invertar) mannual. [Descriptions and critics of tests. Normal values]. Universität Erlangen, Nürnberg 4; 1986.
32. Pék Gy, Fülöp T. Hungarian version of the NAI (Nürnberger Alters Invertar) [in Hungarian], Orvosi Hetilap. 1991;42:2319-2322.
33. Manconi E, Binagli F, Pitzus F. A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative oirgin. Curr Ther Res. 1986;40:702-709.
34. Balesteri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987;35:425-430.
35. Blaha L, Erzigkeit H, Adamczyk A, et al. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Hum Psychopharmacol. 1989;4:103-111.
36. Bönöczk P, Pánczél G, Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound. 2002;15: 85-91.
37. Orlandi G, Murri L. Transcranial Doppler assessment of cerebral flow velocity at rest and during voluntary movements in young and elderly healthy subjects. Int J Neurosci. 1996;84:45-53.